Argentina’s ESKD treatment market is relatively mature, with strong government support and a high incidence of CKD among the elderly and diabetic populations. The country’s public and private healthcare systems work in tandem to provide dialysis and transplant care.
Key drivers include universal healthcare access, government subsidies for dialysis, and well-established nephrology networks in major cities like Buenos Aires, Córdoba, and Rosario. Argentina also has one of the highest organ donation rates in Latin America.
Restraints include economic instability affecting public health funding, disparities in rural healthcare access, and outdated dialysis equipment in some public centers. Additionally, inflation impacts the procurement of imported medical supplies.
Trends show growing adoption of automated peritoneal dialysis, investment in local production of dialysis consumables, and integration of AI-based clinical decision tools. There’s also growing collaboration between research institutions and hospitals to enhance early CKD intervention.
Opportunities exist in modernizing rural healthcare infrastructure, strengthening transplant logistics, and increasing awareness about CKD among high-risk populations. With a skilled medical workforce and proactive public health system, Argentina offers a stable foundation for continued ESKD market growth.
TABLE - Argentina End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Treatment Type 2021-2033
Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Hemodialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Peritoneal Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Kidney Transplantation | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Deceased Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Living Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Medications & Supportive Care | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Immunosuppressants | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Erythropoiesis-Stimulating Agents (ESA) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
- Phosphate Binders | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Argentina End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Modality 2021-2033
Modality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In-Center Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Home Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Argentina End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By End-User 2021-2033
End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Dialysis Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Homecare Settings | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Research & Academic Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Others | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis